These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11489070)

  • 1. Secondary prevention of cardiovascular disease and diabetes: still suboptimal in patients with myocardial infarction.
    Chin BS; Kharim S; Ghaffar A; Rehman A; Lip GY
    J Intern Med; 2001 Aug; 250(2):180-2. PubMed ID: 11489070
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome.
    Ergatoudes C; Thunström E; Rosengren A; Björck L; Bengtsson Boström K; Falk K; Fu M
    BMC Cardiovasc Disord; 2016 Nov; 16(1):226. PubMed ID: 27855640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice.
    Grimes RT; Ensor J; Bennett K; Henman MC
    Prim Care Diabetes; 2016 Aug; 10(4):237-43. PubMed ID: 26654852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments regarding "a systematic review of implementation of established recommended secondary prevention measures in PAOD".
    Lindahl AK
    Eur J Vasc Endovasc Surg; 2010 Jan; 39(1):87-8. PubMed ID: 19906546
    [No Abstract]   [Full Text] [Related]  

  • 6. [The Swedish Bjorknas study: fewer physician visits in primary health care. A randomized study of intensive life style intervention].
    Osterlind J; Eriksson MK; Ostenson CG; Eliasson M
    Lakartidningen; 2010 Apr 14-20; 107(15):976-80. PubMed ID: 20464913
    [No Abstract]   [Full Text] [Related]  

  • 7. Organ protection in the secondary prevention of type 2 diabetes.
    Schernthaner G
    Drugs Today (Barc); 2006 Dec; 42 Suppl C():17-23. PubMed ID: 17245477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice.
    Filippi A; Paolini I; Innocenti F; Mazzaglia G; Battaggia A; Brignoli O
    J Hum Hypertens; 2009 Nov; 23(11):758-63. PubMed ID: 19242492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of implementation of established recommended secondary prevention measures in patients with PAOD.
    Flu HC; Tamsma JT; Lindeman JH; Hamming JF; Lardenoye JH
    Eur J Vasc Endovasc Surg; 2010 Jan; 39(1):70-86. PubMed ID: 19910222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
    Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Implementation of clinical guidelines in general practice. The effect of journal audit and continuing education for the treatment of cardiovascular risk factors in patients with and without type 2 diabetes].
    Madsbad S; Larsen ML; Adeler HF; Kryhlmand M; Westergaard M
    Ugeskr Laeger; 2006 Apr; 168(17):1640-5. PubMed ID: 16674875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge for preventive cardiology.
    Kotseva K; Wood D
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S19-23. PubMed ID: 19675431
    [No Abstract]   [Full Text] [Related]  

  • 13. Hope for the future: early recognition of increased cardiovascular risk in children and how to deal with it.
    Masi S; Charakida M; Wang G; O'Neill F; Taddei S; Deanfield J
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S61-4. PubMed ID: 19675441
    [No Abstract]   [Full Text] [Related]  

  • 14. Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention.
    Kones R
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):61-81. PubMed ID: 21183531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factor management: a practice guide.
    Perk J
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S24-8. PubMed ID: 19675433
    [No Abstract]   [Full Text] [Related]  

  • 16. National study of physician awareness and adherence to cardiovascular disease prevention guidelines.
    Mosca L; Linfante AH; Benjamin EJ; Berra K; Hayes SN; Walsh BW; Fabunmi RP; Kwan J; Mills T; Simpson SL
    Circulation; 2005 Feb; 111(4):499-510. PubMed ID: 15687140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.
    Tan SS; Rutten FF; Hakkaart-van Roijen L
    J Eval Clin Pract; 2011 Dec; 17(6):1094-101. PubMed ID: 21040249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic control and morbidity of type 2 diabetic patients in a general practice network.
    Bouma M; Dekker JH; van Eijk JT; Schellevis FG; Kriegsman DM; Heine RJ
    Fam Pract; 1999 Aug; 16(4):402-6. PubMed ID: 10493712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New guidelines for the prevention of cardiovascular disease.
    Klemsdal TO; Gjelsvik B; Elling I; Johansen S; Kjeldsen SE; Kristensen Ø; Madsen S; Njølstad I; Selmer R; Tonstad S; Voie H
    Tidsskr Nor Laegeforen; 2017 Sep; 137(16):. PubMed ID: 28871738
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of type 2 diabetes mellitus: is it in accordance with the guidelines?
    Chan GC; Ghazali O; Khoo EM
    Med J Malaysia; 2005 Dec; 60(5):578-84. PubMed ID: 16515108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.